Sign In
Buy CVS
$98.32
-0.84 (-0.85%)
At Close: Jun 18, 2026
Does A 7.6% Dividend Make Walgreens A Better Buy Than CVS?
07:11am, Tuesday, 29'th Aug 2023
Very rarely do investors get the opportunity to consider a purchase of a high-quality asset or company at a steep discount to the overall industry it operates within. Today, there is not only one name
CVS launches new brand targeting biosimilar market
04:49pm, Thursday, 24'th Aug 2023
CVS Health Corporation (CVS) is entering the biosimilar space with its new subsidiary brand Cordavis. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down what the brand entails and its imp
CVS Health launches subsidiary to produce biosimilar drugs
05:32pm, Wednesday, 23'rd Aug 2023
CNBC's Bertha Coombs joins 'Closing Bell Overtime' to talk news that CVS Health is launching a subsidiary to make biosimilar drugs to Humira.
CVS Health launches biosimilars subsidiary, will commercialize Humira competitor
04:36pm, Wednesday, 23'rd Aug 2023
CVS Health Corp. CVS, -0.97% said Wednesday that it has launched a new subsidiary that will work directly with drugmakers to co-produce and commercialize biosimilars. The subsidiary, Cordavis, has con
CVS launches unit to market and co-produce biosimilars
04:26pm, Wednesday, 23'rd Aug 2023
CVS Health Corp said on Wednesday it has launched Cordavis, a unit that will work directly with manufacturers to commercialize and co-produce biosimilars for the U.S. market.
CVS Health Launches Company To Produce Cheaper ‘Biosimilar' Versions Of Expensive Biotech Drugs
04:25pm, Wednesday, 23'rd Aug 2023
CVS Health is launching a new company, Cordavis, to commercialize and produce biosimilar drugs, the cheaper versions of expensive prescriptions derived from biotechnology.
CVS pushes further into generic drugs with Sandoz partnership for new discount Humira
04:18pm, Wednesday, 23'rd Aug 2023
CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.
3 Pharma Stocks to Buy as Summer COVID Cases Spike
05:11am, Wednesday, 23'rd Aug 2023
Covid-19 related stocks started spiking again this week. Driven primarily by reports about new variants and increasing spread.
Health care stocks under pressure after Blue Shield of CA drops CVS as pharmacy benefit manager
01:26pm, Monday, 21'st Aug 2023
Yahoo Finance Health Care Reporter Anjalee Khemlani reports on Blue Shield of California dropping CVS as pharmacy benefits manager and her conversation with Blue Shield of California CEO Paul Markovic
Want to Get Rich? 3 Game-Changing Stocks to Buy Right Now
06:15pm, Friday, 18'th Aug 2023
Navigating the stock market is a journey mixed with analysis, timing, and good fortune. But for those looking at wealth accumulation, there's always the burning question: which are the stocks to buy t
CVS Stock Price Predictions: What to Know as Analysts Cut CVS Price Targets
02:59pm, Friday, 18'th Aug 2023
Shares of retail pharmacy chain CVS Health (NYSE: CVS ) only managed modest gains during Friday's afternoon session, an unremarkable consolation following yesterday's dramatic implosion. Sparking the
Lee Munson explains why investors should bail on Nvidia, Expedia and CVS Health
02:24pm, Friday, 18'th Aug 2023
Lee Munson, Portfolio Wealth Advisors president and CIO, joins 'The Exchange' to discuss how to trade hedge fund filing names, Expedia's struggle to compete against credit card points, and the competi
Is Trending Stock CVS Health Corporation (CVS) a Buy Now?
10:19am, Friday, 18'th Aug 2023
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Sees Stock-Price Targets Cut. It Could Still Be a Buy.
08:54am, Friday, 18'th Aug 2023
Blue Shield of California's decision not to use the PBM, which negotiates prices on behalf of insurers, is a setback for CVS and a risk for other PBMs.
Everybody will sell first and ask questions later with PBM stocks: E Squared's Les Funtleyder
06:45pm, Thursday, 17'th Aug 2023
Les Funtleyder, E Squared healthcare portfolio manager, joins 'Fast Money' to talk the PBM business model's viability after Blue Shield of California dropped CVS in favor of Amazon and Cost Plus Drugs
